Drug repurposing is emerging as an important strategy in modern pharmaceutical research because it can identify new therapeutic uses for existing medicines and potentially reduce the time, cost, and uncertainty associated with conventional drug development. The latest trend is the integration of artificial intelligence, machine learning, generative AI, and large-scale biomedical datasets into repurposing workflows. AI systems can analyze relationships between drugs, diseases, genes, proteins, clinical records, and molecular pathways to identify potential treatment opportunities. At the same time, the AI pharmaceutical industry is moving toward more integrated discovery platforms that combine computational prediction with laboratory and clinical validation.

As per research, The global artificial intelligence in drug repurposing market size was valued at USD 1.3 billion in 2025 and is projected to grow from USD 1.7 billion in 2026, at a CAGR of 24.5% from 2026 to 2033. Rising demand for cost-effective drug development, increasing clinical trials in drug repurposing, and growing prevalence of rare and complex diseases are significant factors contributing to market growth.

The expansion of AI in drug repurposing is supported by the growing availability of biomedical information, including electronic health records, clinical trial data, genomic databases, scientific publications, and molecular datasets. Researchers can use these resources to discover previously unknown relationships between existing drugs and disease mechanisms. This approach is particularly valuable for rare diseases and complex conditions where conventional discovery programs can require substantial time and financial investment.

AI in Drug Repurposing

AI in drug repurposing is changing how researchers prioritize drug candidates and identify new therapeutic indications. Machine learning models can examine large datasets to detect patterns that may not be easily identified through traditional research methods. These systems can evaluate drug-target interactions, disease pathways, molecular signatures, patient characteristics, and treatment outcomes to generate potential repurposing hypotheses.

One major advantage of AI-supported repurposing is its ability to accelerate candidate screening. Instead of testing every existing compound individually, computational models can rank potential candidates according to their predicted effectiveness against a specific disease. Researchers can then focus laboratory experiments and clinical investigations on the most promising options.

Generative AI in Drug Discovery

Generative AI in drug discovery is becoming another important development across the pharmaceutical industry. While traditional AI models are primarily used for prediction and classification, generative systems can help create or modify molecular structures, propose potential drug candidates, and generate hypotheses around drug-target relationships.

In drug repurposing, generative AI can support the exploration of alternative mechanisms of action and identify potential combinations involving existing medicines. It can also help researchers summarize scientific literature and connect findings across multiple sources. When integrated with molecular modeling and biological datasets, generative AI can contribute to faster hypothesis generation and more efficient research workflows.

However, AI-generated predictions still require careful scientific evaluation. Explainable AI and clinical validation are becoming increasingly important because researchers and regulators need to understand why an algorithm identifies a particular drug-disease relationship and whether the prediction can be supported by experimental and clinical evidence.

AI Pharmaceutical Industry Transformation

The AI pharmaceutical industry is increasingly adopting intelligent platforms throughout the drug development lifecycle. Pharmaceutical companies, biotechnology firms, research organizations, and technology providers are combining AI with automation, cloud computing, high-performance computing, and advanced analytics.

AI can assist in target identification, compound screening, biomarker discovery, clinical trial design, patient stratification, and safety assessment. For repurposing programs, these capabilities can help connect existing medicines with new disease indications while improving the efficiency of research teams.

The integration of AI with outsourced pharmaceutical development is also becoming relevant. Pharmaceutical CDMOs are increasingly adopting automation, robotics, and AI-powered data analytics to improve manufacturing precision, quality control, and operational timelines. This broader adoption of advanced technologies supports pharmaceutical companies as they move promising therapies from research toward clinical and commercial applications.

The increasing prevalence of chronic, rare, and complex diseases is creating strong demand for faster therapeutic development approaches. Existing medicines with established safety information can provide an attractive starting point for identifying new treatments. Rising healthcare expenditure, increasing pharmaceutical R&D investments, and growing availability of clinical and molecular datasets are further supporting the adoption of computational repurposing approaches.

Another opportunity is the growing use of multimodal data. Multimodal AI for drug-disease prediction can combine information from different sources, including molecular structures, medical imaging, clinical records, genomic data, and scientific literature. By analyzing these data types together, AI models can potentially develop a broader understanding of disease biology and drug response.